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ABSTRACT 
Interleukin (IL)-6 is known to cause pro- and anti-inflammatory effects during different stages 
of inflammation. Recent therapeutic investigations have focused on treatment of various in-
flammatory disorders with anti-cytokine substances. As a result, the aim of this study was to 
further elucidate the influence of IL-6 in hyperalgesia and edema during different stages of 
Complete Freund’s Adjuvant (CFA)-induced arthritis (AA) in male Wistar rats. AA was in-
duced by a single subcutaneous injection of CFA into the rats’ hindpaw. Anti-IL-6 was ad-
ministered either daily or weekly during the 21 days of study. Spinal mu opioid receptor 
(mOR) expression was detected by Western blotting. Daily and weekly treatment with an 
anti-IL-6 antibody significantly decreased paw edema in the AA group compared to the AA 
control group. Additionally, daily and weekly anti-IL-6 administration significantly reduced 
hyperalgesia on day 7 in the AA group compared to the AA control group; however, there 
were significant increases in hyperalgesia in the antibody-treated group on days 14 and 21 
compared to the AA control group. IL-6 antibody-induced increases in hyperalgesia on the 
14th and 21st days after CFA injection correlated with a time-dependent, significant reduction 
in spinal mOR expression during anti-IL-6 treatment. Our study confirmed the important 
time-dependent relationship between serum IL-6 levels and hyperalgesia during AA. These 
results suggest that the stages of inflammation in AA must be considered for anti-hyperalgesic 
and anti-inflammatory interventions via anti-IL-6 antibody treatment. 
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INTRODUCTION 
Inflammation results in rapid elevation 
of the secretion of inflammatory mediators, 
chemokines and cytokines, such as inter-
leukins 1 and 6 (IL-1 and IL-6) and tumour 
necrosis factor α (TNFα). Inflammatory 
substances play a role in pain modulation 
by interfering with nociceptive transduc-
tion, conduction and transmission. Increas-
ing evidence has demonstrated the impor-
tance of cytokines in acute and chronic pain 
(De Jongh et al., 2003a). IL-6 is a pleio-
tropic cytokine and was originally identi-
fied as a T-cell-derived B-cell differentia-
tion factor, which showed different actions 
on various biological systems. Deregulation 
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of IL-6 expression causes the synthesis and 
release of many inflammatory mediators, 
which may result in pain (Nishimoto and 
Kishimot, 2006). Due to its multiple stimu-
latory effects on cells of the immune system 
and vascular endothelial cells, it is believed 
that excess IL-6 plays a pathogenic role in 
the development of inflammation, resulting 
in hyperalgesia and edema (De Jongh et al., 
2003b). Modulation of immune responses 
to alleviate pain and inflammation has been 
of interest for many years. Due to the cen-
tral role played by IL-6 in a number of 
manifestations of inflammatory diseases, 
therapeutic inhibition of IL-6 represents a 
novel approach to the treatment of chronic 
inflammation. Studies have demonstrated 
that some symptoms of inflammation with a 
significant cytokine component, such as 
rheumatoid arthritis, can be treated by inhi-
bition of IL-6 (Van Snick, 1990). However, 
IL-6 has been shown to elicit both pro- and 
anti-inflammatory effects. IL-6 was shown 
to induce analgesia in an animal model of 
inflammation by contributing to the activa-
tion of the endogenous opioid system, 
which is induced in response to peripheral 
inflammation (Möller and Villiger, 2006). 
Complete Freund’s Adjuvant (CFA)-
induced arthritis (AA) in rats is an inflam-
matory model widely used in etiopatho-
genic investigational drug and molecular 
studies due to its similarity to human rheu-
matoid arthritis (RA). It has been shown 
that local injection of CFA in rats increases 
local and systemic secretion of cytokines, 
such as IL-1, IL-6 and TNFα (Zhang et al., 
1998). Our previous study revealed that 
CFA-induced hyperalgesia on the 7th day 
following CFA injection was correlated 
with increases in inflammatory mediators, 
such as IL-6; however, hyperalgesia was 
found to be significantly reduced by the 3rd 
week. We hypothesised that activation of 
opioids is differentially regulated during 
different stages of AA, and these changes 
may be induced by variations in the secre-
tion of certain mediators during inflamma-
tion. Mu-opioid receptors (mOR) are con-
sidered to be an important mediator of the 
analgesic effects of opioids. Mu-opioid re-
ceptors (mORs) are also up-regulated in 
inflammation, which may contribute to the 
anti-nociceptive effects of endogenous 
opioids (Zaringhalam et al., 2007). More-
over, Pol and Puig (2004) have demon-
strated that mice with an IL-6 deficiency 
have reduced analgesic responses to mor-
phine (mOR agonist) and a lower mOR re-
ceptor density in the grey matter of the 
midbrain (Pol and Puig, 2004). Further 
studies are necessary to evaluate the exact 
roles of IL-6 in pain after various forms of 
tissue or nerve injury. As a result of the two 
proposed roles of IL-6 during inflammation 
and recent investigations using anti-
cytokine therapies to treat inflammatory 
disorders in several different animal models 
(Van Snick, 1990), we designed this study 
to further elucidate the influence of IL-6 in 
hyperalgesia and edema during different 
stages of CFA-induced arthritis (AA) by 
examining the effects of anti-IL-6 treatment 
on spinal mOR expression.  
 
MATERIALS AND METHODS 
Laboratory animals  
Adult male Wistar rats, weighing 200–
220 g were used in all experiments. Rats 
were housed in polypropylene cages under 
hygienic and standard environmental condi-
tions (22 ± 2 ºC, humidity 60-70 %, 12 h 
light/dark cycle). The animals were allowed 
for standard food and water. Each animal 
was used once only. All procedures were 
approved by the local ethics committee for 
the use of animals in research and we fol-
lowed the guidelines of ethical standards 
for investigations of experimental pain in 
animals (Zimmermann, 1983).  
 
Induction of adjuvant arthritis (AA) 
AA was induced at day 0 as expressed 
in our previous studies. Briefly, a single 
subcutaneous injection (100 µl) of heat-
killed mycobacterium tuberculosis sus-
pended in sterile mineral oil (10 mg/ml), 
CFA (Sigma, St. Louis, MO/USA), into the 
left hind paw was performed. Left hind 
paws of control rats were injected with ster-
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ile mineral oil only (100  µl). First day after 
CFA injection unilateral inflammation was 
established in injected hindpaw, then first 
week was considered as inflammatory 
phase. The third week after intervention 
was arthritic phase (Zaringhalam et al., 
2007). 
 
Assessment of CFA-induced arthritis (AA) 
Arthritis due to CFA injection was as-
sessed by measurements of paw volumes 
pre- and post-injection (on days 0, 7, 14 and 
21). Measurements (paw volume) were 
conducted by displacement of an electrolyte 
solution in a plethysmometer (model 7141; 
Ugo Basile; Comerio VA, Italy), as de-
scribed previously by our lab (Rezazadeh et 
al., 2009). Briefly, the rats’ hindpaws were 
submerged up to the tibiotarsal joint in the 
electrolyte-filled Perspex cell of the 
plethysmometer. The volume of liquid dis-
placement, which is correlated to the paw 
volume, was indicated on a digital display. 
Volume measurements were conducted 
twice for each paw, and the average volume 
displacement was calculated. The edema 
was quantified by measuring the difference 
in foot volume between day 0 and subse-
quent time points. The volumes measured 
on days post-injection were calculated as 
the percentage of the day 0 volume. 
 
Behavioral test: Thermal hyperalgesia as-
sessment 
Paw withdrawal latency (PWL) from 
noxious heat by using the plantar test (Ugo 
Basile, Verse, Italy) was assessed in differ-
ent experimental and control rats on days 0, 
7, 14, and 21 as previously described (Za-
ringhalam et al., 2007) . Rats were placed in 
Plexiglas boxes for 10–15 min before test-
ing in order to habituate to test environ-
ment. PWL automatically recorded by digi-
tal timer which connected to the heat 
source. If the rat did not withdraw its paw 
from stimulus by 20 s, the test was termi-
nated and it was assigned as cut-off value. 
Withdrawal latency was measured three 
times for each hindpaw at an interval of 5–
10 min and the mean latency was calcu-
lated. Then, the mean value for the affected 
paw (CFA-injected paw) was subtracted 
from that for the other paw and the result 
considered as the hyperalgesia sign in the 
injured paw. 
 
Blood sampling and serum IL-6 measure-
ments 
The serum IL-6 levels of the rats were 
assayed by a rat standard ELISA kit 
(Bender Med System, UK) on day 0 (before 
CFA injection) and on days 7 (inflamma-
tory phase), 14 and 21 (arthritic phase) fol-
lowing CFA injection (Zaringhalam et al., 
2007). Rats were lightly anesthetised with 
methoxyflurane and retro-orbitally bled into 
heparinised tubes during the experimental 
procedure. The samples were centrifuged 
and stored at -70 °C. Blood samplings were 
done simultaneously for each group (8-8:15 
AM). The collected serum showed 100 % 
cross-reactivity with the ELISA kit, and the 
limit of serum IL-6 detection was 
31.2 pg/ml. ELISA assays were performed 
according to the manufacturer’s protocol. 
 
Anti-IL-6 antibody administration 
To further evaluate the role of IL-6 in 
AA symptoms, rats were treated with poly-
clonal anti-IL-6 antibodies to deplete serum 
IL-6 levels. The anti-rat IL-6 antibody was 
obtained from R&D Systems (Abcam/UK). 
This antibody was produced in goats im-
munised with purified, Escherichia coli-
derived, recombinant rat IL-6. In addition, 
some investigators have demonstrated reac-
tivity of this antibody preparation in vivo in 
rat models (Agarwal et al., 2010). Accord-
ing to the manufacturer, the neutralisation 
dose 50 (ND50) for this anti-rat IL-6 anti-
body (catalogue number ab9770) was ap-
proximately 0.003-0.005 µg/ml in the pres-
ence of 0.1 ng/ml rat IL-6. The IL-6 neu-
tralising antibody was dissolved in sterile 
phosphate-buffered saline (PBS) for intra-
peritoneal (i.p.) injection, and control ani-
mals received PBS. This solution was pre-
pared fresh at a maximum of 30 min prior 
to injection.  
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Spinal mOR expression detection by West-
ern blotting 
After behavioral tests, Western blot was 
used to examine the variations of mOR ex-
pression in spinal cord as previously was 
described (Back et al., 2006). Rats were 
sacrificed under isoflorane anesthesia, indi-
vidual spinal cords were rapidly removed 
on ice and homogenized (Brinkman Poly-
tron Homogenizer, 20.000 rpm 30 s) in ex-
traction buffer containing a cocktail of pro-
teinase inhibitors (50 mM Tris–HCl, 
pH 7.5, 150 mM NaCl, 1 mM ethylenedia-
minetetraacetic acid (EDTA), 1 % NP40, 
0.5 % sodium dodecyl sulfate (SDS), 1 mM 
sodium orthovanadate, 2.5 µg/ml aprotinin, 
2 µg/ml leupetin, 2 µg/ml pepstatin A). 
Then, boiled for 5 min and centrifuged at 
10.000 rpm (15 °C) for 10 min. The super-
natant was removed for analysis and protein 
concentration was determined (Bradford, 
1976). (Equal amounts of protein (60 µg) 
were diluted with loading buffer (4 % SDS, 
25 mM Tris–HCl pH 6.8, 5 % glycerol, 
0.5 % 2-mercaptoethanol, 0.005 % bromo-
phenol blue). After boiling for 10 min, an 
aliquot of the diluted sample (12 µl) was 
loaded on polyacrylamide gels (Pager Gels 
10 % Tris-Glycine, Bio-Rad) and samples 
were separated by electrophoresis (120 V 
for 60 min). A sample from an individual 
spinal cord was loaded on each lane. Pro-
teins were transferred to Immobilon-P 
PVDF membranes (Millipore, Bedford, 
MA) using the miniprotean II (Bio-Rad) at 
100 V for 85 min. Nonspecific binding sites 
on the membrane were blocked by incuba-
tion (90 min at 24 °C or overnight at 4 °C) 
in blocking buffer (0.2% Aurora Blocking 
Reagent; 1X Phosphate Buffered Saline: 
0.058 M Na2HPO4, 0.017 M NaH2PO4, 
0.068 M NaCl; 0.05 % Tween-20 from ICN 
Biomedicals, Costa Mesa, CA) followed by 
incubation (1 h, 24 °C) with primary anti-
body in blocking buffer (Rabbit polyclonal 
IgG for mOR (1:1000); Abcam/CA). Mem-
branes were washed twice with blocking 
buffer and then incubated (1 h, 24 °C) with 
secondary antibody in blocking buffer (An-
ti-rabbit IgG (1:10000), Abcam/CA). 
Membranes were then washed thrice with 
blocking buffer, followed by two quick 
rinses with assay buffer (20 mM Tris-HCl, 
pH 9.8, 1 mM MgCl2). The immunoreactiv-
ity of the proteins on the membrane was 
visualized using the chemiluminescence 
detection system (ECL, Amersham). The 
membranes were then incubated in strip-
ping buffer (100 µM 2-mercaptoethanol, 
2 % SDS, 62.5 mM Tris [pH 6.7]) at 50 °C 
for 30 min and reprobed with beta-actin 
primary antibody (1:5000; Cell Signaling) 
as a loading control. Band intensity was 
measured densitometrically using NIH Im-
age (1.60), and expressed as the ratio of the 
intensity of the mOR band to that of β-actin 
to account for any differences in starting 
mOR proteins. Each experiment was repli-
cated three times with new groups of rats. 
 
Experimental procedures 
Rats were randomly divided into differ-
ent experimental groups (n=6-7 per group). 
AA was induced by subcutaneous injection 
of CFA in the left hindpaw on day 0 (under 
light anaesthesia) in experimental groups. 
To determine the effects of serum IL-6 lev-
els on pain and edema and whether a time-
dependent relationship exists, different ex-
periments were performed. A neutralising 
dose of anti-IL-6 diluted in PBS (0.1 µg/ml) 
was injected (i.p.) from the first day after 
CFA injection until the 21st day of the 
study, either daily or weekly (Liang et al., 
2009; Serada et al., 2008). As different 
phases were described for CFA-induced 
AA (Cicala et al., 2000; Taniguchi et al., 
2004), the molecular, behavioural, paw 
edema and serum IL-6 levels were assessed 
on day 0 (immediately before CFA injec-
tion), and on days 7 (inflammatory phase), 
14 and 21 (arthritic phase), 30 min before 
anti-IL-6 administration. Spinal mOR ex-
pression was assessed by Western blotting 
on days 0, 7, 14 and 21 in AA, AA plus 
anti-IL-6 (either daily or weekly injections) 
and AA plus PBS (vehicle) groups. This 
procedure was also applied in control 
groups. Animals were killed by decapita-
tion at the end of each experiment (under 
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methoxyflurane anaesthesia), and whole 
spines were dissected, immediately snap-
frozen in liquid nitrogen and kept at -80 °C 
until mOR expression assessment was con-
ducted by Western blot. 
 
Statistical analysis 
Data are presented as mean ± standard 
error of mean (SEM). Western blot experi-
ments were replicated two or three times, 
and the results were analysed by perform-
ing an unpaired t-test. Thermal hyperalge-
sia, paw edema and serum IL-6 levels were 
analysed by one-way analysis of variance 
(ANOVA) (Statistica 6). Post hoc analysis 
was performed with Tukey’s multiple com-
parison test where appropriate. Statistical 
significance was accepted at P<0.05. 
 
RESULTS 
Paw edema variations during different 
stages of AA  
CFA injection increased ipsilateral paw 
(left paw) volume, which was continuous 
until the 21st day of the study. Paw volume 
significantly increased on the 7th, 14th and 
21st days after CFA injection compared to 
day 0. Paw volume was significantly in-
creased on the 21st day compared to the 7th 
and 14th days after CFA injection (P<0.01 
and P<0.05, respectively). Daily and 
weekly anti-IL-6 antibody administration 
(i.p.) in the AA group significantly reduced 
paw edema compared to the AA control 
group throughout this study (P<0.001). 
However, even with anti-IL-6 antibody 
treatment, the volume of the injected paw 
was significantly greater on days 7, 14 and 
21 than on day 0 (P<0.001). There were no 
significant differences in reduction in paw 
volume between daily and weekly anti-IL-6 
treatment. Additionally, there were no sig-
nificant differences in paw volume between 
CFA injected rats and rats injected with 
CFA and treated with vehicle, PBS (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: CFA injection caused significant edema in affected paw which continued till 21 days of AA. 
Anti-IL-6 antibody treatment significantly reduced inflamed paw volume. Data are presented as mean 
± SEM (n=6/group). ***P<0.001 indicate significant increase in CFA injected paw during different days 
of study compared to day 0. ### P<0.001 comparison of paw volume variation between CFA and 
CFA+ anti-IL-6 antibody treated rats. 
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Variations in thermal hyperalgesia during 
different stages of AA  
Thermal hyperalgesia varied in the left 
(injected) paw during different stages of 
AA. Hyperalgesia significantly increased 
on the 7th day after CFA injection compared 
to day 0 (P<0.001). PWL measurements in 
the AA group indicated that hyperalgesia 
significantly decreased on the 14th and 21st 
days after CFA injection compared to day 7 
(P<0.001). There was a significant decrease 
in hyperalgesia on the 21st day compared to 
day 14 after CFA injection (P<0.001). 
Daily or weekly anti-IL-6 antibody admini-
stration in AA rats significantly reduced 
hyperalgesia on the 7th day after CFA injec-
tion compared to the AA group (P<0.001), 
but these two antibody-treated experimental 
groups showed significant increases in hy-
peralgesia on days 14 and 21 compared to 
the AA control group (P<0.01 and P<0.001, 
respectively). There were no significant dif-
ferences in hyperalgesia between daily 
treatment with anti-IL-6 antibody (i.p.) and 
weekly administration. Also, there were no 
significant differences in hyperalgesia dur-
ing different phases of AA between the 
CFA injected group and the CFA injected 
group given PBS vehicle (Fig. 2).  
 
Variations in serum IL-6 levels during dif-
ferent stages of AA  
CFA injection caused significant in-
creases in serum IL-6 levels on the 7th, 14th 
and 21st days after CFA injection compared 
to day 0 (P<0.001). Anti-IL-6 antibody 
treatment reduced serum IL-6 levels to near 
basal levels (day 0). Daily or weekly treat-
ment of AA groups with an anti-IL-6 anti-
body significantly attenuated serum IL-6 
levels on the 7th, 14th and 21st days com-
pared to the AA group (P<0.001). There 
were no significant differences in serum IL-
6 levels between daily and weekly anti-IL-6 
antibody treated groups. Groups treated 
with CFA or CFA plus PBS showed no sig-
nificant differences in serum IL-6 levels 
(Fig. 3).  
 
Hyperalgesia variations
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Fig. 2: CFA injection into the hind paw of rats cause significant hyperalgesia at 7th day but, hyperalge-
sia reduced at 14th and 21st days. Daily/weekly administration of anti-IL-6 changed hyperalgesic pro-
cedure during AA. Data are presented as mean ± SEM (n=6/group). *** P<0.001, **P<0.01, *P<0.05 
for comparing the hyperalgesia between day 0 and other days of AA. ###P<0.001 for comparing hy-
peralgesia variation between day 7 and other days in AA group. +++P<0.001, ++P<0.01 Indicate hy-
peralgesia difference between CFA and CFA+ anti-IL-6 antibody treated groups.  
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Serum IL-6 level variation
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Fig. 3: Serum IL-6 level significantly increased during different stages of AA. Anti-IL-6 antibody treat-
ment during AA caused significant reduction in serum IL-6 level. Data are presented as mean ± SEM 
(n=6/group). ***P<0.001 indicate serum IL-6 increase during different stages of AA compared to day 0. 
### P<0.001 comparison of serum IL-6 level variation between CFA and CFA+ anti-IL-6 antibody 
treated rats. 
 
 
Variations in spinal mOR expression dur-
ing different stages of AA  
Western blot analysis of mOR protein 
expression showed similar bands with mo-
lecular masses of approximately 48 kDa in 
tissue from the spinal cords of all experi-
mental groups, which is consistent with ear-
lier reports. Immunospecificity was con-
firmed by the absence of immunoreactive 
bands when the membrane was pre-
incubated with an antigenic peptide prior to 
antibody incubation (data not shown). Fol-
lowing quantification of mOR-immuno-
reactive bands, membranes were stripped 
and re-probed for β-actin as a loading con-
trol (43 kDa) (Fig. 4). To normalise differ-
ences in protein-loading, all data were ex-
pressed as mOR/β-actin ratios. Analysis by 
densitometry demonstrated that AA time-
dependently led to a significant increase in 
spinal mOR protein expression when com-
pared to the control group. There was no 
significant increase in spinal mOR on the 
7th day after AA (3 ± 1.15 %) compared to 
day 0 (2 ± 1.2 %). Results indicated that 
spinal mOR expression was significantly 
increased on days 14 (28.4± 1.3 %) and 21 
(54± 1.15 %) following CFA injection com-
pared to day 0 (P<0.001 for both). Spinal 
cord mOR protein expression in AA groups 
significantly increased on the 21st day com-
pared to the 14th day after CFA injection 
(P<0.001) (Fig. 5). 
 
 
Fig. 4: Immunoblots of mOR receptor protein 
extracted from the spinal cord during different 
stages of AA (days 0, 7, 14, 21).  
Lanes:  
1: Control group 
2: AA group 
3: AA+PBS group 
4: Daily anti-IL-6 antibody received group 
5: Weekly anti-IL-6 antibody received group. 
β-actin was considered as a loading control. 
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Fig. 5: CFA injection caused significant increase in spinal mOR expression time dependently. Anti-IL-
6 antibody administration significantly reduced spinal mOR expression during different stages of AA. 
Ratio of spinal mOR protein band intensity in AA group significantly decreased at 14th and 21st days 
after anti-IL-6 antibody treatment compared to AA control group. Data are presented as mean ± SEM 
(n=6/group). +++ P<0.001 comparison of ratio of spinal mOR protein band intensity between different 
days of AA. ** P<0.01, ***P<0.001 comparison of spinal mOR protein band intensity between AA and 
AA+ anti-IL-6 antibody treated rats. ### P<0.001 indicated spinal mOR protein band intensity differ-
ence in AA and AA + anti-IL-6 antibody treated rats between 14th and 21st days. 
 
 
The effect of anti-IL-6 antibody treatment 
on spinal mOR expression during different 
stages of AA  
Daily or weekly treatment with an anti-
IL-6 antibody significantly reduced spinal 
mOR protein expression in a time-depend-
ent manner. Anti-IL-6 antibody administra-
tion caused a significant reduction in spinal 
mOR protein expression on the 14th (11.9 ± 
2.1 %) and 21st (8.5 ± 1.8 %) days follow-
ing CFA injection, compared to AA control 
groups (P<0.01 and P<0.001, respectively); 
however, spinal mOR expression on days 
14 and 21 was significantly higher than on 
day 0 (P<0.01). There were no significant 
differences in spinal mOR protein expres-
sion between daily and weekly anti-IL-6 
antibody treatment groups on different days 
of study. Statistical analysis showed that 
mean spinal mOR protein expression de-
creased due to anti-IL-6 antibody treatment 
on the 21st day after AA compared to the 
AA control group and was significantly 
higher than on day 14 (P<0.001). PBS ad-
ministration in AA rats, the anti-IL-6 anti-
body vehicle, did not change spinal mOR 
protein expression compared to the AA 
group (Fig. 5). 
 
DISCUSSION 
The immune and nervous systems ex-
press similar molecules, such as cytokines 
and neurotransmitter receptors, which fa-
cilitate the bidirectional coordination be-
tween these two systems. This coordination 
is essential for managing and modulating 
the immunoneurobiological responses to 
stressors such as inflammation. The analge-
sic effects of peripherally applied opioids 
are augmented under conditions of tissue 
injury and inflammation (Zöllner et al., 
2003). Our study, in addition to previous 
studies, demonstrated that one of the under-
lying mechanisms of these effects is the up-
regulation of spinal mOR under persistent 
inflammatory conditions. Cytokines may 
play an important role in this mechanism by 
up-regulating mOR expression in the cen-
tral nervous system and peripheral tissues. 
IL-6 is a multifunctional cytokine with pro- 
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and anti-inflammatory properties. IL-6 me-
diates both acute and chronic phases of in-
flammatory responses and is therefore in-
volved in both early and late stages of in-
flammation (Möller and Villiger, 2006). 
Our investigation showed that AA-
associated inflammation increased serum 
IL-6 levels, which remained elevated until 
the 21st day after initiating AA by CFA in-
jection. Circulating serum IL-6 has been 
shown to be increased in multiple inflam-
matory diseases, including RA, systemic 
juvenile idiopathic arthritis and Crohn's dis-
ease (Van Snick, 1990). A clear correlation 
between IL-6 levels and different markers 
of inflammation was established in patients 
with RA; however, IL-6 induces a variety 
of opposing effects in the nervous system, 
which are not well understood (Leon, 
2002). Our study demonstrated that serum 
IL-6 time-dependently affects hyperalgesia 
during different stages of AA. During first 
week of study, daily or weekly systemic 
administration of anti-IL-6 reduced hyper-
algesia. We predicted this effect because 
previous studies have demonstrated that the 
hyperalgesic responses of AA in the acute 
phase are partially related to the release of 
cytokines, such as IL-1, IL-6 and TNFα, 
which can directly or indirectly stimulate 
nociceptors (De Jongh et al., 2003a). IL-6 is 
one of the chief stimulators of the produc-
tion of most acute phase proteins and is 
critical in controlling the extent of local and 
systemic acute inflammatory responses, 
such as hyperalgesia (Van Snick, 1990). As 
a result, these data and the findings of this 
study suggest that IL-6 may play an impor-
tant role in the induction of hyperalgesia 
during the inflammatory (acute) phase of 
CFA-induced AA. Anti-IL-6 antibody (i.p.) 
administration in AA rats significantly alle-
viated paw edema on all days of investiga-
tion. This might be due to IL-6 stimulatory 
roles on endothelial cell production, release 
of IL-8 and monocyte-derived chemo-
attractant proteins, expression of adhesion 
molecules and recruitment of leukocytes to 
inflammatory sites (Lipsky, 2006), which 
can be blocked by anti-IL-6 antibody treat-
ment. Other animal studies have demon-
strated that IL-6 is critical in the develop-
ment of experimental arthritis (edema). The 
development of carrageenan-induced arthri-
tis in anti-mouse IL-6 antibody-treated mice 
was significantly inhibited (Takagi et al., 
1998). Anti-IL-6 antibody treatment during 
this study reduced paw edema in AA rats; 
however, affected paw volumes of anti-IL-6 
antibody treated rats was higher than on day 
zero (before CFA injection). Several media-
tors, such as histamine and bradykinins, and 
cytokines, such as, IL-1, TNF α and IL-6, 
are thought to influence inflammation 
(Möller and Villiger, 2006). Therefore, con-
tinuation of paw edema despite treatment 
with a neutralising dose of anti-IL-6 anti-
body during AA was expected.  
Furthermore, our results indicated that 
spinal mOR expression on the 14th and 21st 
days of AA increased with concurrent de-
creases in hyperalgesia. These findings, in 
addition to our previous study, which re-
vealed that naloxone (as mOR antagonist) 
has hyperalgesic effects on the 21st day of 
AA, confirm the important role of spinal 
mOR in decreasing hyperalgesia during the 
chronic phase (arthritic phase) of AA. It has 
been shown that the transition from acute to 
chronic inflammation is likely to involve 
several systems, including changes in cyto-
kine signalling both centrally and peripher-
ally; however, the mechanisms involved in 
these changes are poorly understood 
(Vadivelu and Sinatra, 2005). The pattern 
of cytokine production and secretion in the 
acute and chronic phase responses varies in 
different inflammatory conditions. IL-6 is 
important cytokine for transitioning be-
tween acute and chronic inflammation, and 
it is involved in different stages of RA (Ni-
shimoto and Kishimot, 2006). Some studies 
have indicated that IL-6 exhibits pro-
inflammatory features in carrageenan-
induced chronic inflammation and induces 
hyperalgesia (Takagi et al., 1998), but our 
results demonstrated anti-inflammatory ef-
fects of serum IL-6 during the chronic 
phase of AA. Our study emphasised that 
systemic anti-IL-6 antibody administration 
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(either daily or weekly) reduced spinal 
mOR expression during the chronic phase 
of AA and subsequently increased hyperal-
gesia. These different findings concerning 
the hyperalgesic roles of IL-6 during 
chronic inflammation may be due to differ-
ent models of inflammation, the time of in-
flammatory symptom assessment and dif-
ferent methods of assessing IL-6 levels 
(both local and systemic). In this in vivo 
study, we assessed the role of systemic and 
chronic increases of IL-6 levels on hyperal-
gesia induced by CFA injection. Moreover, 
our results and results from previous studies 
demonstrated that IL-6 administered one 
week after injection of CFA into the rats’ 
hindpaw resulted in immediate analgesia 
(<5 min), which was blocked by naloxone. 
This analgesia for sustained inflammatory 
pain was attributed to a local release of en-
dogenous opioid peptides by immune cells 
after IL-6 challenge. Some studies have 
also shown that IL-6 can induce mOR 
mRNA up-regulation in a human neuroblas-
toma cell line (SH SY5Y cells) (De Jongh 
et al., 2003b). It has been suggested that IL-
6 may serve as a regulator of inflammatory 
pain and may be essential in the immuno-
opioid pathway (De Jongh et al., 2003a). 
Therefore, it is expected that at least part of 
the anti-hyperalgesic effect of serum IL-6 
during the arthritic (chronic) phase of AA 
can be mediated via increases in spinal 
mOR expression. Our results also demon-
strated that daily or weekly administration 
of a neutralising dose of anti-IL-6 antibody 
(0.1 µg/ml) was effective at reducing ele-
vated serum IL-6 levels during AA, and 
there were no significant differences be-
tween daily and weekly injections. This 
suggests that a maximum threshold of anti-
IL-6 activity may be achieved at or even 
below the 0.1 µg/ml/week dose level; thus, 
the current study cannot provide pharma-
cokinetic data on the efficacy of anti-IL-6 
antibody therapy beyond the observation of 
a marked reduction in disease parameters. 
In sum, this study confirmed the important 
time-dependent relationship between serum 
IL-6 levels and CFA-induced inflammation. 
An important finding of this study was that 
increases in serum IL-6 levels reduced hy-
peralgesia during the chronic (arthritic) 
phase of AA, which may be mediated by 
increased spinal mOR expression. On the 
other hand, due to the central role played by 
IL-6 in some manifestations of inflamma-
tory diseases, inhibition of IL-6 may pro-
vide a novel approach for the treatment of 
RA. However, our study suggests that the 
stages of arthritis must be considered for 
anti-hyperalgesic and anti-inflammatory 
intervention via anti-IL-6 antibody treat-
ment. Additional studies are necessary to 
establish the procedure of anti-IL-6 anti-
body treatment in the clinic. 
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